The Lynx Group
Cholangiocarcinoma News

September 2022, Vol 3, No 3

First-line treatment options are limited to gemcitabine/cisplatin (GemCis) for patients with advanced cholangiocarcinoma (CCA).
Read More

Surgery remains the only potentially curative modality for cholangiocarcinoma (CCA) in any site of origin.
Read More

On September 2, 2022, the US Food and Drug Administration approved durvalumab in combination with gemcitabine/cisplatin for advanced biliary tract cancers (BTCs) on the basis of the TOPAZ-1 study.
Read More

The Cholangiocarcinoma Foundation hosts a patient registry, the International Cholangiocarcinoma Patient Registry (ICPR), that is a global database comprising patient medical histories and treatments for cholangiocarcinoma (CCA).
Read More

Pemigatinib is an oral, potent, selective fibroblast growth factor receptor (FGFR)1-3 inhibitor that is currently approved for the treatment of adults with previously treated, unresectable, locally advanced/metastatic cholangiocarcinoma (CCA) bearing an FGFR2 fusion or other rearrangement based on the FIGHT-202 trial.
Read More

Results of the randomized, double-blind, global, phase 3 TOPAZ-1 trial (NCT03875235) demonstrated that the first-line chemoimmunotherapy regimen of the PD-L1 inhibitor durvalumab plus gemcitabine/cisplatin (GemCis; median follow-up, 13.7 months) significantly improved overall survival (OS) versus placebo plus GemCis (median follow-up, 12.6 months).1
Read More

Results of the randomized, double-blind, global, phase 3 TOPAZ-1 trial (NCT03875235) demonstrated that the first-line chemoimmunotherapy regimen of the PD-L1 inhibitor durvalumab plus gemcitabine/cisplatin (GemCis; median follow-up, 13.7 months) significantly improved overall survival (OS) versus placebo plus GemCis (median follow-up, 12.6 months).1
Read More

The randomized, open-label, multicenter, phase 3 ABC-06 trial established folinic acid/fluorouracil/oxaliplatin chemotherapy (FOLFOX) plus active symptom control (ASC) as the standard-of-care second-line treatment in patients with advanced biliary tract cancers (BTCs).1
Read More

Although the clinical relevance of quality of life (QOL) is increasingly being acknowledged, it is rarely included as a clinical study end point in biliary tract cancers (BTCs).
Read More

Adjuvant capecitabine (CAP) is the current standard of care as adjuvant therapy for patients with resected cholangiocarcinoma (CCA); however, patient outcomes are still suboptimal.
Read More

Page 1 of 2


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: